12:00 AM
 | 
Apr 28, 2008
 |  BioCentury  |  Finance

Progenics chronicles

Progenics chronicles

Progenics' stock has had a bumpy ride from the newsflow related to the methylnaltrexone compound it in-licensed from UR Labs in 2001. The company ended last week up 95% - gaining $6.52 to $13.40 - on FDA approval and a positive CHMP opinion for the subcutaneous formulation of Relistor, an opioid receptor antagonist, to treat opioid-induced constipation (OIC). Indeed, just last month, the stock dropped 64% the day the company announced negative preliminary Phase III data on the IV...

Read the full 381 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >